Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureTamara Jones, Andreia Ferreira Moura, Waleed Alrjoub, Cecilie Delphin Amdal, Johannes M. Giesinger, Alexandra Gilbert, Mogens Groenvold, Hayat Hamzeh, Zsuzsanna Iyizoba, Michael Koller, Dagmara Kuliś, Julia Lai-Kwon, Jammbe Musoro, Madeline Pe, Morten Aa. Petersen, Omar Shamieh, Galina Velikova, Florian Zeman, Claire Piccinin, Sandra Nolte
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review
10.1093/jnci/djr541 · 2012
Quality of life among long-term (⩾5years) colorectal cancer survivors – Systematic review.
10.1016/j.ejca.2010.06.010 · 2010
Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy
10.1002/cncr.31133 · 2018
Validity of a single-item indicator of treatment side effect bother in a diverse sample of cancer patients
2022
How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?
2022
The FACT-GP5 as a global tolerability measure: responsiveness and robustness to missing assessments
10.1007/s11136-024-03740-x · 2024
Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial
10.1200/jco.23.00377 · 2024
Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes
10.1093/jnci/djp386 · 2009
Impact of oxaliplatin-induced neuropathy: a patient perspective
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
2012
Symptom experience of patients undergoing treatment for multiple myeloma: a longitudinal real-world electronic patient-reported outcomes study
2024
Real-world patient-reported outcomes and concordance between patient and physician reporting of side effects across lines of therapy in multiple myeloma within the USA
2023
The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review
2016
Inter-rater reliability of CTCAE assessments with or without EORTC patient-reported outcome data in a mixed cancer population: a multinational, open-label, randomised controlled trial
10.1016/s1470-2045(25)00679-5 · 2026
An implementation study of electronic assessment of patient-reported outcomes in inpatient radiation oncology
10.1186/s41687-022-00478-3 · 2022
Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms
10.1158/1078-0432.ccr-15-2035 · 2016
Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop
10.1016/j.jval.2017.09.009 · 2018
Broadening the definition of tolerability in cancer clinical trials to capture the patient experience
2020
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
The Functional Assessment of Cancer Therapy scale: development and validation of the general measure
10.1200/jco.1993.11.3.570 · 1993
Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer
1999
Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder
10.1038/bjc.2016.284 · 2016
Unresolved referenced work
Kept as external metadata until matched
Telling more than we can know: Verbal reports on mental processes
10.1037/0033-295x.84.3.231 · 1977
Updated methodological guidance for the conduct of scoping reviews
10.11124/jbies-20-00167 · 2020
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
10.1136/bmj.n71 · 2021
Single-Item Measures of Side-Effect
2025
Beyond PICO: the SPIDER tool for qualitative evidence synthesis
10.1177/1049732312452938 · 2012
Unresolved referenced work
Kept as external metadata until matched
Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21
10.1038/sj.bjc.6606086 · 2011
Development and validation of the functional assessment of cancer therapy-antiangiogenesis subscale
10.1002/cam4.385 · 2015
Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19
10.1093/oncolo/oyad028 · 2023
Comparability of interview- and self-administration of the Functional Assessment of Cancer Therapy-General (FACT-G) in English- and Spanish-speaking ambulatory cancer patients
10.1097/mlr.0b013e3181648e6e · 2008
Validity of a single-item indicator of treatment side effect bother in patients with head and neck cancer
2024
Association Between Physician- and Patient-Reported Symptoms in Patients Treated With Definitive Radiation Therapy for Locally Advanced Lung Cancer in a Statewide Consortium
10.1016/j.ijrobp.2021.11.024 · 2022
The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma
10.3109/10428194.2012.711830 · 2013
Validity, reliability, responsiveness, and clinically meaningful change threshold estimates of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16)
10.1186/s41687-024-00776-y · 2024
Comparison of Simple-Summated Scoring and Toxicity Index Scoring of Symptom Bother in the NSABP B-30 Clinical Trial
10.1007/s11482-022-10103-6 · 2023
Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOG-ACRIN Cancer Research Group (E1302)
10.1002/cam4.3506 · 2020
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
10.1016/s1053-4296(03)00031-6 · doi-reference
Statistical controversies in clinical research: Value of adverse events relatedness to study treatment: analyses of data from randomized double-blind placebo-controlled clinical trials
10.1093/annonc/mdx043 · doi-reference
Assessing side-effect bother, burden, and tolerability: A qualitative study exploring the content validity of the Functional Assessment of Cancer Therapy - Item GP5
10.1016/j.jgo.2025.102304 · doi-reference
10.1186/s12955-019-1162-5
10.1186/s12955-019-1162-5 · doi-reference
Content validity of the NCCN-FACT ovarian symptom index-18 (NFOSI-18)
10.1016/j.ygyno.2014.12.002 · doi-reference
An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study
10.2196/10004 · doi-reference
Comparative Analysis of Paper-Based and Web-Based Versions of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16) Questionnaire in Breast Cancer Patients: Randomized Crossover Study
10.2196/18269 · doi-reference
Psychometrics of patient-reported bother from side effects of treatment single-items in industry-sponsored oncology trials
10.1007/s11136-023-03426-w · doi-reference
Exploration of baseline patient-reported side effect bother from cancer therapy
10.1177/1740774520910389 · doi-reference
Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma
10.1016/j.jval.2018.04.1371 · doi-reference
Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer
10.1186/s41687-024-00823-8 · doi-reference
Overall side effect assessment of oxaliplatin toxicity in rectal cancer patients in NRG oncology/NSABP R04
10.1007/s11136-024-03746-5 · doi-reference
Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma
10.1001/jamanetworkopen.2024.3854 · doi-reference
Reliability, validity, and change thresholds of the NCCN/FACT Bladder Symptom Index (NFBlSI-18) in patients with advanced urothelial cancer
10.1002/cncr.35025 · doi-reference